Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy

NCT01796301 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01796301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01796301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
May 14, 2015
Enrollment
436 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis